Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy.
Diabetic cardiomyopathy is characterized by reduced cardiac contractility independent of vascular disease. A contributor to contractile dysfunction in the diabetic heart is impaired sarcoplasmic reticulum function with reduced sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA2a) pump activity, leading to disturbed intracellular calcium handling. It is currently unclear whether increasing SERCA2a activity in hearts with existing diabetic cardiomyopathy could still improve calcium flux and contractile performance. To test this hypothesis, we generated a cardiac-specific tetracycline-inducible double transgenic mouse, which allows for doxycycline (DOX)-based inducible SERCA2a expression in which DOX exposure turns on SERCA2a expression. Isolated cardiomyocytes and Langendorff perfused hearts from streptozotocin-induced diabetic mice were studied. Our results show that total SERCA2a protein levels were decreased in the diabetic mice by 60% compared with control. SERCA2a increased above control values in the diabetic mice after DOX. Dysfunctional contractility in the diabetic cardiomyocyte was restored to normal by induction of SERCA2a expression. Calcium transients from diabetic cardiomyocytes showed a delayed rate of diastolic calcium decay of 66%, which was reverted toward normal after SERCA2a expression induced by DOX. Global cardiac function assessed in the diabetic perfused heart showed diminished left ventricular pressure, rate of contraction, and relaxation. These parameters were returned to control values by SERCA2a expression. In conclusion, we have used mice allowing for inducible expression of SERCA2a and could demonstrate that increased expression of SERCA2a leads to improved cardiac function in mice with an already established diabetic cardiomyopathy in absence of detrimental effects.
Suarez
Jorge
J
Dept. of Medicine, 5063 Basic Sciences Bldg., Univ. of California, San Diego, La Jolla, CA 92093-0618, USA.
Scott
Brian
B
Dillmann
Wolfgang H
WH
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015153:Blotting, Western; D002118:Calcium / Q000378:metabolism*; D020013:Calcium Signaling / Q000502:physiology; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology*; D004318:Doxycycline / Q000494:pharmacology; D004452:Echocardiography; D006352:Heart Ventricles; D066298:In Vitro Techniques; D051379:Mice; D008822:Mice, Transgenic; D009200:Myocardial Contraction / Q000235:genetics / Q000502:physiology*; D032383:Myocytes, Cardiac / Q000502:physiology; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000096:biosynthesis* / Q000235:genetics
D000900:Anti-Bacterial Agents; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D004318:Doxycycline; D002118:Calcium
Transgenic Res. 2001 Jun;10(3):269-75
11437283
Diabetes. 2002 Apr;51(4):1166-71
11916940
Curr Hypertens Rep. 2004 Dec;6(6):424-9
15527685
Diabetes. 1978 Feb;27(2):127-34
624442
Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2164-72
15256372
Am J Cardiol. 1972 Nov 8;30(6):595-602
4263660
Am J Physiol Heart Circ Physiol. 2004 Jan;286(1):H68-75
12958030
Am J Physiol. 1983 Jun;244(6):E528-35
6134470
Diabetes. 2001 Sep;50(9):2133-8
11522681
Am J Physiol Heart Circ Physiol. 2007 Apr;292(4):H1755-63
17142343
Cell Calcium. 2007 Oct-Nov;42(4-5):503-12
17509680
Circ Res. 2001 Jul 20;89(2):160-7
11463723
J Mol Cell Cardiol. 2000 Apr;32(4):655-64
10756121
J Mol Cell Cardiol. 1997 Jul;29(7):1985-90
9236152
J Mol Cell Cardiol. 2001 Jun;33(6):1053-63
11444913
Mol Ther. 2006 May;13(5):987-96
16503203
J Clin Invest. 1997 Jul 15;100(2):380-9
9218515
Am Heart J. 1975 Feb;89(2):153-8
1114942
FASEB J. 2002 Oct;16(12):1657-9
12206992
Circulation. 1997 Jul 15;96(2):400-3
9244202